Evidence map›Paper›PMID 34841076›Full record

ArticleClinical mass spectrometry (Del Mar, Calif.)2019

A sensitive method for the simultaneous UHPLC-MS/MS analysis of milrinone and dobutamine in blood plasma using NH

Kalev Takkis, Rūta Veigure, Tuuli Metsvaht, Maarja Hallik, Mari-Liis Ilmoja, Joel Starkopf, Karin Kipper

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical mass spectrometry (Del Mar, Calif.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. High-Throughput Quantitative LC-MS/MS Analysis of Barbiturates in Human Urine.Methods in molecular biology (Clifton, N.J.) · 2024
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Kalev TakkisUniversity of Tartu, Institute of Chemistry, 14a Ravila Street, 50411 Tartu, Estonia.
Rūta VeigureUniversity of Tartu, Institute of Chemistry, 14a Ravila Street, 50411 Tartu, Estonia.
Tuuli MetsvahtTartu University Hospital, Lunini 6, 51014 Tartu, Estonia.
Maarja HallikDepartment of Anaesthesiology and Intensive Care, Institute of Clinical Medicine, Tartu University, L. Puusepa 8 - G1. 209, 50406 Tartu, Estonia.
Mari-Liis IlmojaDepartment of Anaesthesiology and Intensive Care, Tallinn Children's Hospital, Tervise 28, 13419 Tallinn, Estonia.
Joel StarkopfDepartment of Anaesthesiology and Intensive Care, Institute of Clinical Medicine, Tartu University, L. Puusepa 8 - G1. 209, 50406 Tartu, Estonia.
Karin KipperUniversity of Tartu, Institute of Chemistry, 14a Ravila Street, 50411 Tartu, Estonia.
St George's, University of London · GBTallinn Health Care College · EETartu University Hospital · EEUniversity of Tartu · EE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The purpose of this work was to develop and validate an HPLC-MS/MS method suitable for quantifying two important cardiovascular drugs, milrinone and dobutamine, in neonatal and paediatric patients' blood plasma samples. Sufficiently low LLOQ levels were required to obtain adequate pharmacokinetic data for the evaluation of optimal dosing. Since the specifics of the patient group set some restrictions on the available sample volume, the method was designed to use only 20 µL of plasma for the analysis. Analytes were separated chromatographically in a biphenyl column using a conventional water-methanol-formic acid eluent with the addition of ammonium fluoride. The latter provided a significant signal enhancement in positive ion mode detection for both analytes allowing the LLOQ to reach below 1 ng/mL. Matrix matched calibration was linear in the range of 1-300 ng/mL, between-run accuracy remained within 107-115%, and precision within 4.8-7.4% for both analytes over the calibration range (including LLOQ level). Dobutamine degradation in plasma samples was prevented by the usage of ascorbic acid. The method was applied to plasma samples of neonates from two pharmacokinetic/pharmacodynamics studies (n = 38).

Indexed as

Ammonium fluorideAscorbic acidcAMP, cyclic 3,5 adenosine monophosphateCCBV, calculated circulating blood volumeCPD, citrate phosphate dextroseCV, coefficient of variationDobutamineEDTA, ethylenediaminetetraacetic acidEMA, European Medicines AgencyESI, electrospray ionisationEU, European UnionIS, internal standardLC, liquid chromotographyLLOQ, lowest limit of quantificationMED, quality control sample at the concentration between ULOQ and 3xLLOQMeOH, methanolMF, matrix factorMilrinoneMRM, multiple reaction monitoringMS, mass spectrometryMS/MS, tandem mass spectrometryNH4F, ammonium fluoridePCR, polymerase chain reactionPD, pharmacodynamicsPK, pharmacokineticsQC, quality control sampleSignal enhancementTOC, total organic carbonUHPLC-MS/MSUHPLC, ultra-high performance liquid chromotographyULOQ, upper limit of quantification

Identifiers

PMID34841076
PMCPMC8620135
OpenAlexW2922372343

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.